Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Endocrinology and Metabolism|May 1, 1989
Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegalyH J Quabbe, U Plöckinger
Journal of Endocrinological Investigation|December 1, 1991
Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegalyU Plöckinger, H J Quabbe
The Journal of Clinical Endocrinology and Metabolism|December 1, 1990
Gastrointestinal side-effects of octreotide during long-term treatment of acromegalyU Plöckinger, D Dienemann, H J Quabbe
The Journal of Clinical Endocrinology and Metabolism|July 1, 1993
Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH valuesU Plöckinger, R M Liehr, H J Quabbe
European Journal of Endocrinology|May 18, 2019
Long-term growth hormone (GH) replacement of adult GH deficiency (GHD) benefits the heartA Ziagaki, D Blaschke, W Haverkamp, et al.
Diabetes Research and Clinical Practice|October 27, 2009
Problems of diabetes management in the immigrant population in GermanyU Plöckinger, M Topuz, M Langer, et al.
The Journal of Clinical Endocrinology and Metabolism|May 20, 1998
Comparison of low and high dose corticotropin stimulation tests in patients with pituitary diseaseJ Mayenknecht, S Diederich, V Bähr, et al.
Human Genomics|March 11, 2018
2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe diseaseU Plöckinger, V Prasad, A Ziagaki, et al.
Journal of Endocrinological Investigation|March 1, 2018
Multi-centre phase IV trial to investigate the immunogenicity of a new liquid formulation of recombinant human growth hormone in adults with growth hormone deficiencyG Johannsson, K Nespithal, U Plöckinger, et al.
European Journal of Endocrinology|April 1, 1997
Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histologyU Plöckinger, M Bäder, W Hopfenmüller, et al.
Pageof 4